|
1
|
Hayer MK, Edwards NC, Slinn G, Moody WE,
Steeds RP, Ferro CJ, Price AM, Andujar C, Dutton M, Webster R, et
al: A randomized, multicenter, open-label, blinded end point trial
comparing the effects of spironolactone to chlorthalidone on left
ventricular mass in patients with early-stage chronic kidney
disease: Rationale and design of the SPIRO-CKD trial. Am Heart J.
191:37–46. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bouchi R, Nakano Y, Fukuda T, Takeuchi T,
Murakami M, Minami I, Izumiyama H, Hashimoto K, Yoshimoto T and
Ogawa Y: Reduction of visceral fat by liraglutide is associated
with ameliorations of hepatic steatosis, albuminuria, and
micro-inflammation in type 2 diabetic patients with insulin
treatment: A randomized control trial. Endocr J. 64:269–281. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nakamura T, Sato E, Amaha M, Kawagoe Y,
Maeda S and Yamagishi S: Addition of aliskiren to angiotensin II
receptor blockers ameliorates renal tubular injury and reduces
intima media thickness of carotid artery in patients with diabetic
nephropathy. Int J Cardiol. 155:294–296. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gandhi GR, Jothi G, Antony PJ, Balakrishna
K, Paulraj MG, Ignacimuthu S, Stalin A and Al-Dhabi NA: Gallic acid
attenuates high-fat diet fed-streptozotocin-induced insulin
resistance via partial agonism of PPARγ in experimental type 2
diabetic rats and enhances glucose uptake through translocation and
activation of GLUT4 in PI3K/p-Akt signaling pathway. Eur J
Pharmacol. 745:201–216. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tsukahara R, Haniu H, Matsuda Y and
Tsukahara T: The AGP-PPARγ axis promotes oxidative stress and
diabetic endothelial cell dysfunction. Mol Cell Endocrinol.
473:100–113. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fu H, Desvergne B, Ferrari S and Bonnet N:
Impaired musculoskeletal response to age and exercise in PPARβ(−/-)
diabetic mice. Endocrinology. 155:4686–4696. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Antonisamy P, Arasu MV, Dhanasekaran M,
Choi KC, Aravinthan A, Kim NS, Kang CW and Kim JH: Protective
effects of trigonelline against indomethacin-induced gastric ulcer
in rats and potential underlying mechanisms. Food Funct. 7:398–408.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhou JY, Du XH, Zhang Z and Qian GS:
Trigonelline inhibits inflammation and protects β cells to prevent
fetal growth restriction during pregnancy in a mouse model of
diabetes. Pharmacology. 100:209–217. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tharaheswari M, Jayachandra Reddy N, Kumar
R, Varshney KC, Kannan M and Sudha Rani S: Trigonelline and
diosgenin attenuate ER stress, oxidative stress-mediated damage in
pancreas and enhance adipose tissue PPARγ activity in type 2
diabetic rats. Mol Cell Biochem. 396:161–174. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ghule AE, Jadhav SS and Bodhankar SL:
Trigonelline ameliorates diabetic hypertensive nephropathy by
suppression of oxidative stress in kidney and reduction in renal
cell apoptosis and fibrosis in streptozotocin induced neonatal
diabetic (nSTZ) rats. Int Immunopharmacol. 14:740–748. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lindhardt M, Persson F, Currie G, Pontillo
C, Beige J, Delles C, von der Leyen H, Mischak H, Navis G, Noutsou
M, et al: Proteomic prediction and Renin angiotensin aldosterone
system Inhibition prevention Of early diabetic nephRopathy in TYpe
2 diabetic patients with normoalbuminuria (PRIORITY): essential
study design and rationale of a randomised clinical multicentre
trial. BMJ Open. 6:e0103102016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Imai E, Chan JC, Ito S, Yamasaki T,
Kobayashi F, Haneda M and Makino H; ORIENT study investigators, :
Effects of olmesartan on renal and cardiovascular outcomes in type
2 diabetes with overt nephropathy: A multicentre, randomised,
placebo-controlled study. Diabetologia. 54:2978–2986. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tziastoudi M, Stefanidis I, Hadjigeorgiou
GM, Stravodimos K and Zintzaras E: A systematic review and
meta-analysis of genetic association studies for the role of
inflammation and the immune system in diabetic nephropathy. Clin
Kidney J. 10:293–300. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen Y, Liang Y, Hu T, Wei R, Cai C, Wang
P, Wang L, Qiao W and Feng L: Endogenous Nampt upregulation is
associated with diabetic nephropathy inflammatory-fibrosis through
the NF-κB p65 and Sirt1 pathway; NMN alleviates diabetic
nephropathy inflammatory-fibrosis by inhibiting endogenous Nampt.
Exp Ther Med. 14:4181–4193. 2017.PubMed/NCBI
|
|
15
|
Chowdhury AA, Gawali NB, Munshi R and
Juvekar AR: Trigonelline insulates against oxidative stress,
proinflammatory cytokines and restores BDNF levels in
lipopolysaccharide induced cognitive impairment in adult mice.
Metab Brain Dis. 33:681–691. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Suresha BS and Srinivasan K: Fungal
metabolite nigerloxin ameliorates diabetic nephropathy and
gentamicin-induced renal oxidative stress in experimental rats.
Naunyn Schmiedebergs Arch Pharmacol. 387:849–859. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Volpe CMO, Villar-Delfino PH, Dos Anjos
PMF and Nogueira-Machado JA: Cellular death, reactive oxygen
species (ROS) and diabetic complications. Cell Death Dis.
9:1192018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Afifi NA, Ramadan A, Erian EY, Saleh DO,
Sedik AA, Badawi M and El Hotaby W: Trigonelline attenuates hepatic
complications and molecular alterations in high-fat high-fructose
diet-induced insulin resistance in rats. Can J Physiol Pharmacol.
95:427–436. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Irudayaraj SS, Stalin A, Sunil C,
Duraipandiyan V, Al-Dhabi NA and Ignacimuthu S: Antioxidant,
antilipidemic and antidiabetic effects of ficusin with their
effects on GLUT4 translocation and PPARγ expression in type 2
diabetic rats. Chem Biol Interact. 256:85–93. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou Z, Wan J, Hou X, Geng J, Li X and Bai
X: MicroRNA-27a promotes podocyte injury via PPARγ-mediated
β-catenin activation in diabetic nephropathy. Cell Death Dis.
8:e26582017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wasik AA, Dumont V, Tienari J, Nyman TA,
Fogarty CL, Forsblom C, Lehto M, Lehtonen E, Groop PH and Lehtonen
S: Septin 7 reduces nonmuscle myosin IIA activity in the SNAP23
complex and hinders GLUT4 storage vesicle docking and fusion. Exp
Cell Res. 350:336–348. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ge J, Miao JJ, Sun XY and Yu JY: Huangkui
capsule, an extract from Abelmoschus manihot (L.) medic,
improves diabetic nephropathy via activating peroxisome
proliferator-activated receptor (PPAR)-α/γ and attenuating
endoplasmic reticulum stress in rats. J Ethnopharmacol.
189:238–249. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Umapathy D, Krishnamoorthy E,
Mariappanadar V, Viswanathan V and Ramkumar KM: Increased levels of
circulating (TNF-α) is associated with (−308G/A) promoter
polymorphism of TNF-α gene in Diabetic Nephropathy. Int J Biol
Macromol 107B. 2113–2121. 2018. View Article : Google Scholar
|
|
24
|
Jia Z, Xinhua X, Qian Z, Miao Y, Jianping
X, Zhixin W, Yijing L and Mingmin L: PPARγ links maternal
malnutrition and abnormal glucose and lipid metabolism in the
offspring of mice. Yi Chuan. 37:70–76. 2015.PubMed/NCBI
|
|
25
|
Wang X, Shi L, Joyce S, Wang Y and Feng Y:
MDG-1, a potential regulator of PPARα and PPARγ, ameliorates
dyslipidemia in mice. Int J Mol Sci. 18:182017.
|
|
26
|
Wu J, Ding Y, Zhu C, Shao X, Xie X, Lu K
and Wang R: Urinary TNF-α and NGAL are correlated with the
progression of nephropathy in patients with type 2 diabetes. Exp
Ther Med. 6:1482–1488. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
González-Clemente JM, Mauricio D, Richart
C, Broch M, Caixàs A, Megia A, Giménez-Palop O, Simón I,
Martínez-Riquelme A, Giménez-Pérez G, et al: Diabetic neuropathy is
associated with activation of the TNF-alpha system in subjects with
type 1 diabetes mellitus. Clin Endocrinol (Oxf). 63:525–529. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li X, Wu TT, Chen J and Qiu W: Elevated
expression levels of serum insulin-like growth factor-1, tumor
necrosis factor-α and vascular endothelial growth factor 165 might
exacerbate type 2 diabetic nephropathy. J Diabetes Investig.
8:108–114. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kozłowska L, Rydzewski A, Fiderkiewicz B,
Wasińska-Krawczyk A, Grzechnik A and Rosołowska-Huszcz D:
Adiponectin, resistin and leptin response to dietary intervention
in diabetic nephropathy. J Ren Nutr. 20:255–262. 2010. View Article : Google Scholar : PubMed/NCBI
|
